RxDoctor Payments Data

Richard Potts, MD

Family Medicine · Ormond Beach, FLNPI 1790987147

Payments from drug & device makers

$965in general payments, 2019–2025

Across 53 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$222
  • Sunovion Pharmaceuticals Inc.$119
  • AstraZeneca$86
  • Lilly USA, LLC$73
  • Biogen$57
  • Photonicare Inc$50
  • plus $359 from 16 others

What the payments were for

  • Food & beverage$965100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$965 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$222,742
Medicare patients
338
Services billed
2,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$117,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$102,039
TrulicityDulaglutide74$86,520
EliquisApixaban71$81,923
MounjaroTirzepatide57$66,759
JardianceEmpagliflozin32$50,359
RybelsusSemaglutide15$18,158
XareltoRivaroxaban12$17,671
Tresiba Flextouch U-200Insulin Degludec18$17,414
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl161$17,136
FarxigaDapagliflozin Propanediol19$16,770
VraylarCariprazine Hcl12$16,352
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,355
Sumatriptan Succinate46$11,451
JanuviaSitagliptin Phosphate11$10,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$73$153,280131 claims
Novo NordiskOzempic, Rybelsus$222$135,89397 claims
Boehringer IngelheimJardiance, Spiriva Respimat$15$58,37843 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Lokelma$86$39,52468 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$20$17,136161 claims
AbbVieVraylar$23$16,35212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →